Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: Bridgebio - Caught on Camera

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three potential near-term product launches from the company’s late-stage pipeline. Tom Trimarchi, BridgeBi

MarketBeat

This Hot Biotech Stock Just Set New All-Time Highs

BridgeBio Pharma (BBIO) has surged 145% over the past year, reaching an all-time high of $75.10. BBIO maintains a strong technical profile with a 100% “Buy” Barchart opinion. Revenue is projected to grow 123% this year and 79.63% next year, though earnings will dip 61.11% before rebounding 44.41%. Despite bullish...

Barchart

Should You Grab This ‘Strong Buy’ Growth Stock With 56% Upside?

With one blockbuster product, this biotech is gearing up for more product launches next year.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Is This Biotech Stock With 150% Upside a Buy Now?

The high price estimate for BridgeBio Pharma suggests potential upside of 150% in 2025.

Barchart

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17,…

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume…

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease

BridgeBio Pharma Inc (NASDAQ:BBIO) announced promising pharmacodynamic data from the first two participants dosed in CANaspire Phase 1/2 trial of BBP-812, gene therapy for Canavan disease. Canavan disease is an ultra-rare inherited disorder that damages the ability of nerve cells (neurons) in the brain to send and receive messages. Data from the first…

Benzinga

BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced interim Phase 1 data from healthy volunteers, supporting the development of BBP-671 for pantothenate kinase-associated neurodegeneration (PKAN) and organic acidemias. BBP-671 is being developed as a potential therapy for diseases in which coenzyme-A (CoA) metabolism is deficient, including PKAN, propionic acidemia (PA), and methylmalonic acidemia (MMA).…

Benzinga

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. Under the agreement terms, BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in…

Benzinga

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'

BridgeBio Pharma Inc (NASDAQ:BBIO) estimates between $23 million to $25 million in restructuring-related costs, including write-offs of long-lived assets, severance and employee-related costs, and exit and other related costs. “The restructuring initiative included, among other components, consolidation and rationalization of facilities, reprioritization of development programs, and the reduction of our workforce,” the company…

Benzinga

BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial

BridgeBio Pharma Inc (NASDAQ: BBIO)

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market

BridgeBio Pharma Inc (NASDAQ: BBIO) has

Benzinga

Sentynl Buys BridgeBio Pharma's Fosdenopterin Rights In Genetic Disorder

BridgeBio Pharma Inc (NASDAQ: BBIO)

Benzinga

Helsinn, BridgeBio Pharma Amend Infigratinib Pact For Oncology Indications

Helsinn Group and BridgeBio Pharma Inc (NASDAQ: BBIO) have

Organisations

Food and Drug Administration

European Medicines Agency

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Amyotrophic lateral sclerosis

32 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.